CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
C4 Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$2.89+0.13 (+4.52%)
Close on Oct 19, 2026
- Market cap
- $377.71M
- P/E (TTM)
- –
- Dividend yield
- –
Community
Notes and questions about C4 Therapeutics from other investors
No posts about CCCC yet
Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.